UTR Therapeutics Publishes Landmark Preclinical Data, Advances c-MYC Targeting Drug Towards First-in-Human Trials
AI-Generated Summary
UTR Therapeutics Inc. has announced the peer-reviewed publication of compelling preclinical data for its lead candidate, UTRxM1-18, an mRNA destabilizing drug targeting the oncogene c-MYC, in aggressive pancreatic cancer models. The study demonstrated dose-dependent tumor regression and inhibition of metastases, directly supporting the company's Investigational New Drug (IND) submission to the U.S. FDA. This novel RNA Overwriting platform, delivered via proprietary iron-oxide nanocages, aims to address previously 'undruggable' oncogenic drivers and is set to advance into Phase 1 clinical trials.
In a nutshell
This development represents a significant advancement in oncology, introducing a first-in-class therapeutic modality for aggressive, c-MYC-driven cancers. The combination of a novel RNA Overwriting platform with an advanced delivery system holds promise to redefine treatment paradigms for challenging malignancies if successful in human trials.
Source: GlobeNewswire
